ME
VERV

McIlrath & Eck’s Verve Therapeutics VERV Stock Holding History

McIlrath & Eck’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75
Closed -$1.05K – 961
2023
Q4 		$1.05K Hold
75
– – ﹤0.01% 844
2023
Q3 		$995 Hold
75
– – ﹤0.01% 814
2023
Q2 		$1.41K Hold
75
– – ﹤0.01% 804
2023
Q1 		$1.08K Hold
75
– – ﹤0.01% 832
2022
Q4 		$1.45K Hold
75
– – ﹤0.01% 775
2022
Q3 		$3K Hold
75
– – ﹤0.01% 730
2022
Q2 		$1K Hold
75
– – ﹤0.01% 807
2022
Q1 		$2K Hold
75
– – ﹤0.01% 738
2021
Q4 		$3K Hold
75
– – ﹤0.01% 705
2021
Q3 		$4K Buy
+75
New +$4.41K ﹤0.01% 669

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

McIlrath & Eck's VERV Position: Q1 2024 in Review

McIlrath & Eck sold out of Verve Therapeutics (VERV) in Q1 2024, closing a stake of 75 shares — an estimated $1.05K sold.

McIlrath & Eck first reported a position in VERV in Q3 2021 and held it in 10 quarters. The position peaked at $4K in Q3 2021. 163 funds tracked by Wall St. Rank hold VERV as of Q1 2024.

  • McIlrath & Eck reported no remaining Verve Therapeutics position as of Q1 2024 after selling out during the quarter.
  • McIlrath & Eck sold 75 Verve Therapeutics shares in Q1 2024, an estimated $1.05K.
  • McIlrath & Eck first reported a position in Verve Therapeutics in Q3 2021 and held it in 10 quarters.
  • McIlrath & Eck's Verve Therapeutics position peaked at $4K in Q3 2021.
  • 163 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2024.

Based on McIlrath & Eck's 13F filing for Q1 2024, filed 10 May 2024.